Anthropic Built a Wet Lab to Run Its Own Drug Programs. The Losers Are Not Charles River or WuXi — They Are the AI Biotechs Without a Pharma Partner.

Anthropic spent2024 and most of 2025 defining the most-cited voluntary AI safety framework in the industry. The Responsible Scaling Policy v3.0, released Feb. 24, 2026, still gates chemical, biological, radiological, and nuclear capabilities at AI Safety Level 3 — protections the company formally activated in May 2025 and updated as recently as August 2026. Less than five months later, the same organization is hiring molecular biologists, RNA scientists, and protein-and-nucleic-acid characterization experts to run bench experiments on its own balance sheet.

The obvious read — that an AI lab running internal biology work will eat into contract research organization order books — does not survive a quarter of 2026 financials. Biotech funding has now grown for four consecutive quarters, reaching $34.3 billion in Q2 2026, and that money is what flows into preclinical CRO pipelines. Both of the largest Western and Chinese CRDMO/CRO players are raising guidance, not bracing for disruption.

WuXi AppTec's trajectory is even starker. The Chinese CRDMO posted RMB 12.44 billion in Q1 2026 (up 28.8% year over year) and RMB 16.46 billion in Q2, lifting full-year 2026 guidance by 14% on Aug. 2, 2026. The BIOSECURE Act — signed into law Dec. 18, 2025 as part of the FY2026 NDAA — has so far been more of a tailwind than a headwind: a U.S. District Court granted WuXi AppTec a preliminary injunction on Aug. 7, 2026 barring DoD enforcement of its 1260H listing, while federal procurement restrictions cannot bite new contracts until OMB completes the Biotechnology Companies of Concern list (no later than Dec. 2026) and the FAR is updated (potentially mid-to-late 2028).

If Anthropic-as-sponsor doesn't hurt CRL or WuXi directly, it does change the competitive geometry for the standalone AI-native biotech platforms that built entire business models around selling AI-discovered molecules back to pharma. The numbers at Recursion Pharmaceuticals — the most-watched public AI biotech since the NVIDIA partnership in 2023 — show the strain.

Recursion's August 5, 2026 quarterly release offered a small bright spot — Genentech opted in to its first neuroscience target from the Roche collaboration, and a fifth progress-based milestone triggered a $4 million payment in February 2026 — but the structural picture is deteriorating. With pharma now able to license Anthropic's Claude Science and similar platforms directly, the value of \"discovery-as-a-service\" intermediaries is compressing. Compare this with Charles River Laboratories, whose Q2 2026 demand improvement was broad-based across \"global biopharmaceutical and small and mid-sized biotechnology clients\" — including the AI-native biotechs that still need regulated toxicology work the AI labs cannot do themselves.

Three layers matter for the rest of the value chain. Upstream, the AI compute infrastructure play belongs to NVIDIA, whose announced $1 billion drug discovery lab partnership with Eli Lilly — plus its residual stake in Recursion — positions it as the picks-and-shovels beneficiary regardless of which AI lab wins. Midstream, the platform layer is bifurcating: capital-rich frontier AI labs (Anthropic, Alphabet/Isomorphic) absorb the platform-plus-sponsor economics; standalone AI biotechs (Recursion, and private peers like Insitro) face a narrowing lane. Downstream, the Big Pharma winners are those who lock in platform access early — Eli Lilly holds deals with Isomorphic (Jan. 2024, $45M upfront per multi-target) and NVIDIA; Novo Nordisk just signed the Anthropic partnership (Sept. 16, 2026).

Days to quarters: the Reuters scoop does not change2026 CRO fundamentals. Charles River Laboratories is exiting its post-pandemic trough with the strongest net book-to-bill in nearly four years; WuXi AppTec is compounding38% H1 growth and raising guidance by 14%. Biotech funding at $34.3B in Q2 2026 (the fourth straight quarter of growth) is what fills preclinical pipelines, and AI labs running neglected-disease programs do not draw on that same dollar pool. Watch the next two earnings calls (CRL Q3 in early November, WuXi Q3 around the same window) for confirmation.

One to three years: the structural shift is real, but it cuts in a direction most CRO bulls do not expect. The threat to the Charles River Laboratories order book is not Anthropic taking work in-house — it is Anthropic empowering every small-cap biotech to run more candidates into IND-enabling studies faster, which is good for volume but bad for CRO pricing power. The threat to WuXi AppTec is geopolitical, not technological: BIOSECURE Act enforcement timing (FAR update potentially mid-to-late 2028) matters more than Anthropic's lab. The threat to Recursion Pharmaceuticals is existential — its Q2 2026 revenue collapse is the early signal of what happens to a platform when compute-rich AI labs build the same capability in-house and pharma signs platform deals directly.